Company Overview PDF Print E-mail

Leader in First-in-Class Monoclonal Antibodies Focused on the Treatment and Diagnosis of Cancer


Our Mission

Delivering innovative and exceptional biopharmaceutical products to improve patient lives


Our Values:

  • Passion: We have a deep personal drive to improve patients’ lives
  • Innovation: We continuously pursue novel solutions
  • Integrity: We strive to do the right thing every time and accept responsibility for our actions
  • Teamwork: We foster collaboration and work together to achieve goals
  • Adaptability: We readily change to meet new challenges


About Peregrine

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. We are pursuing multiple clinical programs in cancer with our lead product candidate bavituximab. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and outside customers.

For oncology indications, our lead PS-targeting candidate bavituximab, in combination with other therapeutic strategies, has demonstrated promising signs of anti-tumor activity and survival trends in patients with non-small cell lung cancer (NSCLC) and advanced breast cancer.

Strong intellectual property is a valuable asset for Peregrine and we will continue to seek robust patent protection for key areas of our research and development efforts. Our extensive patent portfolio covers a number of technologies, including our drug product candidates and preclinical platforms.

While we are advancing the development of our later-stage product candidates in multiple ongoing clinical programs, we are seeking strategic alliances to broaden the geographic reach of our development programs or to advance our earlier-stage technologies and product candidates. For further information, please contact our Business Development department at: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Bavituximab: A Novel Immunotherapy Candidate in Phase III Clinical Development in Previously Treated Non-Small Cell Lung Cancer

On February 25, 2016, Peregrine announced an update to the company's Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The update was based on the recommendation of the study's Independent Data Monitoring Committee (IDMC) following a pre-specified interim analysis performed after 33% of targeted overall events (patient deaths) in the study were reached. The interim analysis results demonstrated that the bavituximab plus docetaxel combination group is unlikely to achieve the assumptions established at the initiation of the trial.

This analysis also showed that the bavituximab combination group is performing as expected according to the original trial assumptions in terms of overall survival, while the docetaxel group is dramatically outperforming overall survival expectations based on the original trial assumptions and as compared to recently published studies. No new or unexpected safety issues were identified.

As the study continues, data will be collected and will contribute to our understanding of immuno-oncology treatment options.

Avid Bioservices

Unique for a biopharmaceutical company, we have an integrated asset, Avid Bioservices, which provides biomanufacturing services for its clients as well as products for our clinical trials.